Common Cold (Coronaviruses)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Several seasonal human coronaviruses can cause a common cold with a runny or blocked nose, sore throat and cough. These viruses differ from SARS-CoV-2, which causes COVID-19. Most infections improve with supportive care, although infants, older adults and people with underlying illness can develop more serious respiratory disease. Symptoms overlap with other viruses, so symptoms alone cannot identify the cause.

Clinical Definition

Seasonal coronavirus colds are acute upper-respiratory infections caused by HCoV-229E, NL63, OC43 or HKU1. These are enveloped, positive-sense single-stranded RNA viruses. Local epithelial infection and host inflammation cause congestion, rhinorrhea, sore throat and cough. They are one cause of the common-cold syndrome, not its predominant overall cause. SARS-CoV-2 is a distinct coronavirus that can produce overlapping symptoms.

Inciting Event

  • Inhalation of virus-containing respiratory particles released by an infected person can initiate infection.

  • Direct contact with contaminated surfaces followed by touching the nasal mucosa or eyes.

  • Mildly symptomatic or unrecognized infections can contribute to exposure; symptoms do not precisely define the shedding period.

  • Close interpersonal interactions such as coughing, sneezing, or talking in enclosed spaces.

  • Introduction of virus into the upper respiratory tract epithelium initiating infection.

Latency Period

  • Symptoms generally begin a few days after exposure; an incubation of approximately 2-4 days is described for common human coronaviruses.

  • Viral replication and shedding evolve around illness onset; their timing varies by virus and host.

  • Incubation estimates are approximate and should not be treated as a reliable five-day exclusion rule for an individual exposure.

  • Replication in respiratory epithelial cells precedes or accompanies the local inflammatory response.

  • Symptoms reflect epithelial infection and host inflammation; onset cannot be assigned to a universal peak in cytokine release.

Diagnostic Delay

  • Symptoms overlap with other viral upper respiratory infections leading to clinical misattribution.

  • Lack of specific diagnostic tests routinely performed in outpatient settings.

  • Mild and self-limited nature causes patients to delay seeking medical evaluation.

  • Absent fever is compatible with a viral cold and does not exclude influenza or COVID-19.

  • Common cold is often diagnosed clinically without confirmatory laboratory testing.

Clinical Presentation


Signs & Symptoms

  • Nasal congestion and rhinorrhea are hallmark symptoms.

  • Sore throat and mild cough are common.

  • Sneezing and malaise frequently occur.

  • Low-grade fever may be present but is usually mild or absent.

  • Headache and mild myalgias can accompany the illness.

History of Present Illness

  • Initial symptoms include nasal congestion, sneezing, and sore throat progressing over 1-2 days.

  • Discharge may change from clear to thicker or colored during a viral illness; color alone does not establish bacterial infection.

  • Cough can accompany upper-airway irritation and secretions; cough alone does not demonstrate spread to the lower respiratory tract.

  • Symptoms often peak in the first few days and improve over about a week; congestion or cough may last longer. Persistent, worsening or severe symptoms require reassessment.

  • Fever may be mild or absent, but its presence or absence does not reliably distinguish seasonal coronavirus from other infections.

Past Medical History

  • History of frequent upper respiratory infections increases likelihood of recurrent colds.

  • Chronic respiratory conditions such as asthma or allergic rhinitis may exacerbate symptoms.

  • Immunodeficiency states can prolong illness duration and increase complication risk.

  • Recent exposure to infected contacts or attendance at crowded public venues is relevant.

  • No vaccine specifically prevents the four endemic common-cold coronaviruses. COVID-19 vaccines target SARS-CoV-2, and influenza vaccines target influenza viruses.

Family History

  • No known heritable syndromes are associated with susceptibility to common cold coronaviruses.

  • Family members often share exposure risks leading to clustered infections.

  • Genetic predisposition to atopy or asthma may influence symptom severity in some families.

  • A family history alone does not diagnose susceptibility; unusually severe or recurrent infections should be assessed on their own clinical merits.

  • Household transmission is common but does not imply inherited susceptibility.

Physical Exam Findings

  • Nasal mucosa erythema and swelling with clear nasal discharge are common findings.

  • Pharyngeal erythema without exudate is frequently observed.

  • Mild cervical lymphadenopathy may be present.

  • Lungs are often clear in an uncomplicated cold. Wheezing, crackles, hypoxemia or increased work of breathing require assessment for lower-airway disease or another diagnosis.

  • Conjunctival injection can occasionally be seen.

Diagnostic Workup


Diagnostic Criteria

The common-cold syndrome is usually diagnosed clinically; symptoms alone cannot confirm seasonal coronavirus as the cause. Selected respiratory NAAT panels can detect specific endemic coronaviruses, but routine testing is unnecessary for most mild cases. Test for influenza or SARS-CoV-2 when results affect treatment or infection-control decisions, especially in patients at risk of severe illness. Investigate respiratory distress, dehydration, persistent fever or worsening illness.

Pathophysiology


Key Mechanisms

  • Viral spike proteins bind host receptors and permit entry into respiratory epithelial cells; receptor usage differs among coronaviruses.

  • The positive-sense RNA genome is translated after entry. Viral RNA-dependent RNA polymerase supports cytoplasmic genome replication and production of subgenomic RNAs.

  • Local inflammation, edema and altered secretions cause congestion and rhinorrhea; symptoms do not identify a particular viral species.

  • Activation of the innate immune response results in recruitment of neutrophils and lymphocytes to the respiratory mucosa.

  • The lipid envelope and surface spikes distinguish coronaviruses structurally from nonenveloped rhinoviruses, another major cause of colds.

InvolvementDetails
Organs

Nasal cavity is the main organ involved, serving as the site of viral entry and symptom manifestation

Pharynx is involved in symptom development such as sore throat due to viral irritation and inflammation

Tissues

Respiratory epithelium lining the nasal passages is the primary tissue affected by coronavirus infection

Mucosal tissue of the upper airway undergoes inflammation leading to characteristic symptoms of the common cold

Cells

Epithelial cells of the nasal mucosa serve as the primary site of coronavirus infection and replication

Neutrophils infiltrate the nasal mucosa contributing to inflammation and symptom development

Macrophages participate in innate immune response by phagocytosing infected cells and releasing cytokines

Chemical Mediators

Cytokines participate in host responses to infection, but measuring IL-6 is not useful for diagnosing an uncomplicated seasonal-coronavirus cold.

Cold-associated nasal inflammation is not equivalent to IgE-mediated allergic rhinitis; antihistamine response alone does not establish the cause.

Prostaglandins mediate local inflammation and pain in the upper respiratory tract

Treatments


Pharmacological Treatments

  • Analgesics and antipyretics (e.g., acetaminophen, ibuprofen)

    • Mechanism:
      • Acetaminophen reduces pain and fever with little peripheral anti-inflammatory effect. Ibuprofen is an NSAID that inhibits cyclooxygenase and prostaglandin synthesis, reducing pain, fever and inflammation.

    • Side effects:
      • Ibuprofen: GI irritation, ulceration or bleeding

      • Acetaminophen: severe liver toxicity with overdose or duplicate products

      • Ibuprofen: renal injury, especially with dehydration or kidney disease

    • Clinical role:
      • Optional relief of bothersome pain or fever, using age-appropriate dosing and contraindication checks; neither drug treats the virus.

  • Decongestants (e.g., pseudoephedrine, oxymetazoline)

    • Mechanism:
      • Cause vasoconstriction of nasal mucosa to reduce nasal congestion

    • Side effects:
      • Hypertension

      • Insomnia

      • Topical irritation and rebound congestion with prolonged use

    • Clinical role:
      • Short-term relief in suitable patients. Limit topical oxymetazoline to no more than 3 days to reduce rebound congestion; systemic and topical products have different risks.

  • Antihistamines (first-generation)

    • Mechanism:
      • First-generation antihistamines block H1 receptors and often have anticholinergic and sedating effects; a cold is not primarily an allergic reaction.

    • Side effects:
      • Sedation

      • Dry mouth

      • Dizziness

    • Clinical role:
      • At most a small, short-lived benefit in some adults; not routine treatment for children and not a cure. Balance limited benefit against sedation and anticholinergic harm.

Non-pharmacological Treatments

  • Maintain comfortable fluid intake and address dehydration; extra fluids are not a specific antiviral treatment.

  • Rest as needed. Honey may soothe cough in adults and children at least 1 year old; never give honey to infants under 1 year.

  • A clean cool-mist humidifier may improve comfort; avoid scalding steam and keep equipment clean.

  • Saline drops or spray may relieve nasal symptoms. For irrigation, use distilled, sterile or previously boiled and cooled water and clean the device appropriately.

Prevention


Pharmacological Prevention

  • No specific antiviral prophylaxis is available for common cold coronaviruses.

  • Influenza and COVID-19 vaccination protect against their target diseases; neither is a vaccine against the four seasonal common-cold coronaviruses.

  • No routine medication prophylaxis is established for seasonal coronavirus colds. Antibiotics do not prevent or treat these viral infections.

Non-pharmacological Prevention

  • Frequent handwashing with soap reduces viral transmission.

  • Reduce close contact when ill and improve ventilation/cleaner air, especially in crowded indoor settings.

  • Respiratory hygiene including covering coughs and sneezes is essential.

  • Disinfection of surfaces decreases fomite-mediated infection.

  • Use of masks in crowded or high-risk settings can reduce viral spread.

Outcome & Complications


Complications

  • Secondary bacterial sinusitis or otitis media can develop.

  • Exacerbation of asthma or COPD is a common complication.

  • Lower-respiratory disease can occur in vulnerable patients; NL63 is also associated with croup in children.

  • Dehydration from poor oral intake can happen in severe cases.

Short-term Sequelae Long-term Sequelae
  • Persistent cough lasting up to several weeks after symptom resolution.

  • Postnasal drip causing throat irritation.

  • Transient fatigue and malaise during recovery.

  • There are generally no long-term sequelae from common cold coronaviruses in healthy individuals.

  • Recurrent infections may occur due to limited immunity.

  • Persistent or recurrent cough or sinus symptoms merit reassessment; they should not automatically be attributed to ongoing coronavirus infection.

Differential Diagnoses


Common Cold (Coronaviruses) versus Influenza

Common Cold (Coronaviruses)

Influenza

Often gradual, predominantly nasal/throat symptoms with mild or absent fever.

Often abrupt fever, myalgia and fatigue, but mild or afebrile influenza can resemble a cold.

Clinical symptoms do not establish seasonal coronavirus, and a negative influenza test does not prove it.

Influenza NAAT can confirm infection; rapid antigen tests are less sensitive, so a negative result may not exclude it.

Supportive care; no established specific antiviral for the four endemic cold coronaviruses.

Influenza antivirals are most effective early, but severe or high-risk illness can warrant treatment even after 48 hours; response is not a diagnostic test.

Common Cold (Coronaviruses) versus Allergic Rhinitis

Common Cold (Coronaviruses)

Allergic Rhinitis

Acute onset of nasal congestion and rhinorrhea with associated mild sore throat

Recurrent sneezing, nasal congestion, and clear rhinorrhea triggered by allergens

A viral cold is not an IgE-mediated disorder, but preexisting atopy can coexist; IgE or eosinophil values do not establish viral infection.

Allergen-related symptoms and sensitization support allergy; total IgE or blood eosinophilia is neither required nor diagnostic alone.

First-generation antihistamines may provide limited short-term relief in adults, but do not treat the virus.

Antihistamines or intranasal corticosteroids often improve allergic symptoms; response alone is not definitive.

Common Cold (Coronaviruses) versus Bacterial Sinusitis

Common Cold (Coronaviruses)

Bacterial Sinusitis

Typically improves over the first week, although cough or congestion may last longer.

Consider bacterial sinusitis with persistent symptoms over 10 days without improvement, severe onset, or worsening after initial improvement.

Discharge can become colored and facial pressure can occur; neither alone establishes bacterial infection.

Severe fever of at least 39 C with purulent drainage or facial pain for 3-4 days supports bacterial sinusitis in the appropriate clinical setting.

Antibiotics do not treat an uncomplicated viral cold.

Selected bacterial sinusitis warrants antibiotics; improvement or lack of improvement alone is not a reliable etiologic test.

Common Cold (Coronaviruses) versus COVID-19

Common Cold (Coronaviruses)

COVID-19

HCoV-229E, NL63, OC43 or HKU1.

SARS-CoV-2 causes COVID-19.

Usually mild upper-respiratory illness; congestion can affect smell.

Can be mild and cold-like or severe; smell/taste disturbance is variable, and its absence does not exclude COVID-19.

A seasonal-coronavirus NAAT can identify the virus when needed; negative SARS-CoV-2 testing alone does not establish this diagnosis.

Use SARS-CoV-2 NAAT or antigen testing as indicated; one negative antigen test does not exclude infection, and repeat testing or NAAT may be needed.

Common Cold (Coronaviruses) versus Respiratory Syncytial Virus (RSV) Infection

Common Cold (Coronaviruses)

Respiratory Syncytial Virus (RSV) Infection

Affects all ages; infants and older or medically vulnerable adults can develop severe disease.

Affects all ages; bronchiolitis is characteristic in infants, and older or high-risk adults can develop severe disease.

Usually upper-airway symptoms, but wheeze or pneumonia can occur.

Often a mild cold; lower-airway disease can produce wheeze and respiratory distress. Clinical overlap is substantial.

A negative RSV test does not prove seasonal coronavirus infection.

RSV NAAT or antigen testing can support diagnosis when indicated; sensitivity varies with the method and patient population.